Spirair Receives FDA Clearance for SeptAlign, the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation
![](https://spirair.com/wp-content/uploads/2024/03/Group-2308.png)
New therapy provides a minimally invasive option for ENTs to straighten minor deviations in septal cartilage and help address nasal airway obstruction.
Spirair Announces Appointment of Chief Executive Officer
![](https://spirair.com/wp-content/uploads/2024/03/Group-2308.png)
Spirair Announces Appointment of Chief Executive Officer Spirair is entering its next stage of growth as it prepares for commercialization.